ArticleCardio-oncology (London, England)2026

Cardiotoxicity risk in metastatic castration-resistant prostate cancer: enzalutamide versus abiraterone.

Alan H Bryce et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.